By Mill Chart
Last update: Apr 24, 2024
Uncover the hidden value in EXELIXIS INC (NASDAQ:EXEL) as our stock screening tool recommends it as an undervalued choice. NASDAQ:EXEL maintains a robust financial position and offers an attractive pricing perspective. Let's dig deeper into the analysis.
ChartMill provides a Valuation Rating to every stock, ranging from 0 to 10. This rating assesses various valuation aspects, comparing price to earnings and cash flows, while considering factors like profitability and growth. NASDAQ:EXEL boasts a 7 out of 10:
ChartMill employs its own Profitability Rating system for stock evaluation. This score, ranging from 0 to 10, is derived from an analysis of diverse profitability metrics and margins. In the case of NASDAQ:EXEL, the assigned 7 is noteworthy for profitability:
A critical element of ChartMill's stock evaluation is the Health Rating, which spans from 0 to 10. This rating considers multiple health factors, including liquidity and solvency, both in absolute terms and relative to industry peers. NASDAQ:EXEL has received a 7 out of 10:
A key component of ChartMill's stock assessment is the Growth Rating, which spans from 0 to 10. This rating evaluates diverse growth factors, such as EPS and revenue growth, considering both past performance and future projections. NASDAQ:EXEL has received a 5 out of 10:
Every day, new Decent Value stocks can be found on ChartMill in our Decent Value screener.
Check the latest full fundamental report of EXEL for a complete fundamental analysis.
Important Note: The content of this article is not intended as trading advice. It is essential to perform your own analysis and exercise caution when making trading decisions. The article presents observations created by automated analysis but does not guarantee any trading or investment outcomes. Always trade responsibly and make independent judgments.
EXELIXIS INC
NASDAQ:EXEL (5/3/2024, 7:00:01 PM)
After market: 21.9 0 (0%)21.9
-0.22 (-0.99%)
EXEL earnings call for the period ending March 31, 2024.
EXEL stock results show that Exelixis missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Exelixis (NASDAQ:EXEL) just reported results for the first quarter of 2024.Exel...
Learn about the top three biotech stocks to take advantage of these companies' promising futures and pharmaceutical advances.
EXELIXIS INC (NASDAQ:EXEL) Reveals Intriguing Technical Aspects. Here's What You Need to Know.
EXELIXIS INC (NASDAQ:EXEL): good value for what you're paying.
Some of the best opportunities can be found in dips in some of the top biotech stocks to buy. In fact, here are three.
Phenomenal deals can still be found, even with the Nasdaq Composite climbing to a new all-time high.